Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.
Naim Alkhouri, MD
Advertisement
Naim Alkhouri, MD, is Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Disease Program at the Clinical Research Institute of Ohio.
Articles by Naim Alkhouri, MD
Alkhouri explains the importance of differentiating F3 from cirrhosis and the utility of different noninvasive tests for identifying these patients.
Alkhouri explains findings from the phase 2 WAYFIND trial suggesting the potential of semaglutide and cilofexor/firsocostat for MASH cirrhosis.
Alkhouri breaks down recent therapeutic progress in MASH and explains new data on resmetirom’s use in patients with compensated MASH cirrhosis.
Alkhouri reviews data from the trial’s open-label compensated MASH cirrhosis arm demonstrating resmetirom’s impact on liver stiffness and CSPH.
Advertisement
Latest Updated Articles
2025 in Hepatology: New MASLD Therapies, HBV Updates, and MoreDecember 2nd 2025
Advertisement
Advertisement
Trending on HCPLive
1
Prevalence and Recognition of Hypercortisolism
2
Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes
3
Skin of Color Savvy—A New Generation of Dermatology Leadership, With Umayr Shaikh, MPH
4
Distinguishing CSU From Chronic Inducible Urticaria Subtypes
5